Revolution Medicines (RVMD) COO pre-planned sale tied to RSU tax

Rhea-AI Filing Summary

Revolution Medicines, Inc. Chief Operating Officer Margaret A. Horn reported an open-market sale of 4,583 shares of common stock at an average price of $99.4804 per share. After this transaction, she directly holds 157,570 shares. A footnote states the sale was executed under a Rule 10b5-1 instruction letter to satisfy tax withholding obligations related to vesting restricted stock units.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Horn Margaret A

(Last) (First) (Middle)

C/O REVOLUTION MEDICINES, INC.

700 SAGINAW DRIVE

(Street)

REDWOOD CITY CALIFORNIA 94063

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/17/2026		S(1)		4,583	D	$99.4804	157,570(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023.

2. Includes 73,050 RSUs.

	/s/ Jack Anders, as Attorney-in-fact for Margaret Horn	03/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did RVMD’s COO report on this Form 4?

Revolution Medicines’ COO Margaret A. Horn reported selling 4,583 shares of common stock. The shares were sold in an open-market transaction at an average price of $99.4804 per share, as disclosed in the Form 4 filing.

How many Revolution Medicines (RVMD) shares does the COO hold after the sale?

After the reported sale, COO Margaret A. Horn directly holds 157,570 shares of Revolution Medicines common stock. This post-transaction balance is shown in the Form 4 and reflects her remaining direct ownership position following the 4,583-share sale.

Was the RVMD COO’s share sale made under a Rule 10b5-1 plan?

Yes. A footnote explains the transaction was made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023. This indicates the sale was pre-arranged rather than timed discretionarily by the executive.

Why did the RVMD COO sell shares according to the Form 4 footnote?

The footnote states the transaction was intended to satisfy Margaret A. Horn’s tax withholding obligations. These obligations arose from the vesting of restricted stock units after July 15, 2023, and the pre-arranged 10b5-1 instruction letter governed the sale.

Does the RVMD COO hold restricted stock units in addition to common shares?

Yes. A footnote notes that her holdings include 73,050 restricted stock units (RSUs). RSUs represent a right to receive shares in the future upon vesting, separate from the 157,570 shares of common stock held directly after the reported sale.

What is the significance of the 4,583 RVMD shares sold by the COO?

The sale involved 4,583 shares at $99.4804 per share and was executed under a Rule 10b5-1 instruction letter for tax withholding. The transaction appears linked to RSU vesting rather than a discretionary change in long-term ownership.